Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “outperform” rating reissued by Wedbush in a research note issued on Monday. They currently have a $4.00 target price on the biopharmaceutical company’s stock. Wedbush’s target price suggests a potential upside of 349.44% from the company’s current price.
Other research analysts have also issued reports about the company. Zacks Investment Research lowered Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Regulus Therapeutics presently has an average rating of “Hold” and a consensus target price of $2.60.
Regulus Therapeutics (NASDAQ RGLS) opened at $0.89 on Monday. The company has a current ratio of 6.77, a quick ratio of 6.77 and a debt-to-equity ratio of 0.41. Regulus Therapeutics has a 1-year low of $0.79 and a 1-year high of $2.75.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGLS. Wedbush Securities Inc. boosted its stake in Regulus Therapeutics by 10.3% in the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 18,600 shares during the period. LMR Partners LLP bought a new stake in Regulus Therapeutics in the 2nd quarter valued at $164,000. Quantitative Investment Management LLC bought a new stake in Regulus Therapeutics in the 2nd quarter valued at $103,000. GSA Capital Partners LLP bought a new stake in Regulus Therapeutics in the 2nd quarter valued at $139,000. Finally, FMR LLC boosted its stake in Regulus Therapeutics by 0.5% in the 2nd quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock valued at $7,862,000 after purchasing an additional 37,489 shares during the period. Institutional investors and hedge funds own 59.41% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Regulus Therapeutics (RGLS) Rating Reiterated by Wedbush” was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.truebluetribune.com/2017/12/13/regulus-therapeutics-rgls-rating-reiterated-by-wedbush.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.